COMMUNIQUÉS West-GlobeNewswire

Nuvus (NUVG) Signs Letter of Intent With Kunjani Group - Nuvus Brings Its Bio-Agriculture & Blockchain Technology Solutions to Africa

27/04/2018 - 13:17

Kunjani Group Will Hold the Exclusive License for Nuvus Technologies in Sub-Sahara Africa Saint Petersburg, FL, April 27, 2018 (GLOBE NEWSWIRE) -- JOHANNESBURG, SOUTH AFRICA — Nuvus Corp., a pioneer in bio-agricultural [...]

Myriad Genetics to Present at Two Upcoming Healthcare Conferences

27/04/2018 - 13:10

SALT LAKE CITY, April 27, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN ), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled [...]

New Study Finds that 24 Percent of Women Seen in the Obstetrics-Gynecology Setting Met NCCN Guidelines for Hereditary Cancer Genetic Testing

27/04/2018 - 13:05

Results from 3,800 Patient Study Will Be Presented at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting SALT LAKE CITY, April 27, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ [...]

Asterias Biotherapeutics to Present AST-OPC1 Program Update at the Upcoming American Society for Neural Therapy and Repair Conference

27/04/2018 - 13:00

FREMONT, Calif., April 27, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with [...]

miRagen Therapeutics Announces New Data Showing Administration of MRG-110 Improved Tissue Perfusion and Wound Healing in Late Stage Preclinical Studies

27/04/2018 - 13:00

MRG-110 appeared to increase vascularization and reparative tissue formation in treated wounds; miRagen believes results support evaluation in human clinical trials MRG-110 treatment appeared to lead to more wounds [...]

Agios Announces Revised Starting Time of 8:00am ET for Investor Day and First Quarter 2018 Financial Results Webcast on Friday, May 4, 2018

27/04/2018 - 13:00

CAMBRIDGE, Mass., April 27, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO ), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company [...]

Advantagene Announces Clinical Trial Collaboration

27/04/2018 - 13:00

Clinical Study to Combine GMCI™ with Opdivo® (nivolumab) in the Treatment of Malignant Glioma AUBURNDALE, Mass., April 27, 2018 (GLOBE NEWSWIRE) -- Advantagene, Inc. today announced that the company entered into a [...]

AnaptysBio To Participate in Upcoming Investor Conferences

27/04/2018 - 12:30

SAN DIEGO, April 27, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB ), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation [...]

Onconova Therapeutics Announces Pricing of $25.0 Million Upsized Underwritten Public Offering

27/04/2018 - 12:00

NEWTOWN, Pa., April 27, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX ) (“Onconova” or “we”), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug [...]

Aino Health AB (publ): Aino Health AB signs cooperation agreement with Finla Occupational Health

27/04/2018 - 11:02

Aino Health and Finla Occupational Health have signed a cooperation agreement regarding Aino's HealthManager platform. Cooperation with Finla will further expand Aino's partner network and enable scalability and growth [...]

FIT Biotech Oy: APPOINTMENT OF TOMMI HOLOPAINEN AS CFO AND AS A MEMBER OF THE MANAGEMENT TEAM OF FIT BIOTECH

27/04/2018 - 10:00

FIT Biotech Oy Company release 27.4.2018 at 11:00 AM EET APPOINTMENT OF TOMMI HOLOPAINEN AS CFO AND AS A MEMBER OF THE MANAGEMENT TEAM OF FIT BIOTECH Tommi Holopainen, MSc Economics, EMBA, has been appointed as a new [...]

Decision on launch of conditional, voluntary offer

27/04/2018 - 09:55

Company announcement 27 April 2018 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH [...]

GENFIT: First quarter 2018 financial information

27/04/2018 - 08:04

GENFIT: First quarter 2018 financial information (Unaudited financial information under IFRS) Cash and cash equivalents of €255.2 million at March 31, 2018 Revenues for the first three months of 2018 of €37 thousand [...]

GENFIT : Information financière du premier trimestre 2018

27/04/2018 - 08:04

GENFIT : Information financière du premier trimestre 2018 (Données non auditées établies selon les normes IFRS) Trésorerie et équivalents de trésorerie s'élevant à 255,2 millions d'euros au 31 mars 2018 Chiffre d' [...]

Xbrane Biopharma publishes 2017 Annual Report

27/04/2018 - 08:01

Press release 2018-04-27 Xbrane Biopharma AB's annual report for 2017 is now available at the company's website, www.xbrane.com . The annual report is distributed to the shareholders and others that made such request. [...]

Shire plc : Rule 2.9 Announcement

27/04/2018 - 08:01

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 27 April 2018 [...]

Saniona publishes the Annual Report for 2017

27/04/2018 - 08:00

PRESS RELEASE April 27, 2018 Saniona, a leading biotech company in the field of ion channels, today announces that the English version of the Annual report for 2017 is now available on the company’s website www.saniona. [...]

Zealand announces net sales of Soliqua® 100/33 and Lyxumia®/Adlyxin® for the first quarter of 2018

27/04/2018 - 07:34

Company announcement - No. 13/2018 Zealand announces net sales of Soliqua ® 100/33 and Lyxumia ® /Adlyxin ® for the first quarter of 2018 Net sales of Soliqua ® 100/33 and Lyxumia ® /Adlyxin ® of EUR 14.5 million/USD 17 [...]

Sanofi: First-quarter 2018 Business EPS(1) up 1.4% at CER

27/04/2018 - 07:32

Paris, April 27, 2018 First-quarter 2018 Business EPS (1) up 1.4% at CER Q1 2018 Change Change at CER IFRS net sales reported €7,898m -8.7% -0.4% IFRS net income reported €1,016m -82.2% (2) - IFRS EPS reported €0.81 -82 [...]